Phototherapy in Persons With Multiple Sclerosis
Phase 1
- Conditions
- Multiple Sclerosis
- Interventions
- Device: Phototherapy
- Registration Number
- NCT02365259
- Lead Sponsor
- University of Illinois at Urbana-Champaign
- Brief Summary
The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.
- Detailed Description
Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
- Female with multiple sclerosis
Exclusion Criteria
- Inability to stand still in a stabilized fashion without risk of falling for up to 6 minutes
- Known medical history of calcium disorder or knowledge of high calcium levels
- Known medical history of hyper-parathyroidism
- Current supplementation with oral vitamin D
- Known allergy to vitamin D
- History of cancer of any type including but not limited to skin cancer
- Obesity defined as BMI > 30
- Known history of fat malabsorption conditions (i.e., steatorrhea)
- Current use of anti-epileptic medication
- Current use of glucocorticoids
- Fitzpatrick skin types I and VI using the Fitzpatrick skin type analysis
- Recent use of tanning facilities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Phototherapy Phototherapy This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks. Shame phototherapy Phototherapy This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
- Primary Outcome Measures
Name Time Method Change from Baseline in Serum Vitamin D at 4 and 8 weeks 0, 4, and 8 weeks Venous blood will be collected to quantify levels of circulating Vitamin D.
- Secondary Outcome Measures
Name Time Method Change from Baseline in Walking Speed at 4 and 8 weeks 0, 4, and 8 weeks Participants will walking for 25-feet as fast, but safely, as possible on an instrumented gait mat for measuring gait speed.
Change from Baseline in Cognitive Function at 4 and 8 weeks 0, 4, and 8 weeks Participants will complete neuropsychological assessments of processing speed and learning and memory.
Change from Baseline in Mood State at 4 and 8 weeks 0, 4, and 8 weeks Participants will complete a 30-item self-report measure of overall mood.
Trial Locations
- Locations (1)
Exercise Neuroscience Research Laboratory
🇺🇸Urbana, Illinois, United States